Twitter-enabled Mobile Messaging for Smoking Relapse Prevention

This study is currently recruiting participants.
Verified July 2013 by University of California, Irvine
Sponsor:
Information provided by (Responsible Party):
Cornelia Pechmann, University of California, Irvine
ClinicalTrials.gov Identifier:
NCT01602536
First received: May 17, 2012
Last updated: July 30, 2013
Last verified: July 2013

May 17, 2012
July 30, 2013
January 2012
December 2013   (final data collection date for primary outcome measure)
7-day point prevalence abstinence from smoking at 30 days after the quit date [ Time Frame: 30 days after quit date ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01602536 on ClinicalTrials.gov Archive Site
* 7-day point prevalence abstinence from smoking at 7 and 60 days after quit date [ Time Frame: 7 days and 60 days after quit date ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Twitter-enabled Mobile Messaging for Smoking Relapse Prevention
Twitter-enabled Mobile Messaging for Smoking Relapse Prevention

In Phase I (first 12 months), consistent with Aim 1, we have developed a treatment protocol for smoking cessation and relapse prevention that uses virtual quit-smoking Twitter groups and Twitter-enabled interactive peer messaging. We are in the process of testing and refining this protocol using 40 participants in 2 quit-smoking Twitter groups. In Phase II (24 months), consistent with Aim 2, we will conduct a two-condition (test vs. control) randomized controlled trial of the treatment protocol created in Phase I. This research will provide crucial pilot data about the viability and methodology of a larger randomized controlled trial that would directly measure smoking behavior.

Smoking relapse rates remain high, innovative strategies are needed to lower them, and web-based social networking may help like Twitter. This developmental research examines whether providing virtual (web-based) social support to smokers, through Twitter-enabled interactive peer texting, can help smokers quit and avoid relapses. Twitter is a free social networking and micro-blogging service, one of the most advanced and novel technologies available today that can provide social support to smokers, and it is the only service that provides free texting to groups. It is global and has many features that are associated with treatment success including interactive, multi-way, live messaging and mobile accessibility, because the messages go instantly to mobile phones and to the web. It can provide an innovative way to reach smokers who might otherwise not seek treatment, and it can be extended to other health domains.

In Phase II which started in fall 2012, we conducted a two-condition randomized controlled trial (Aim 2). All participants (N=240) received 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start. Participants were also randomly assigned at the individual level to one of two conditions: (1) a virtual quit-smoking Twitter group condition where the group members were instructed to use Twitter-enabled interactive peer messaging to help them quit and stay quit, or (2) a control group condition where the group members were not given this instruction or a Twitter group. In total, there will be 6 Twitter groups and 6 control groups with 20 smokers randomly assigned to each group (i.e., N=120 test, N=120 control). Outcomes include self-reported 7-day point prevalence abstinence at 7, 30 and 60 days after the quit date. Participants' tweets, their virtual and face-to-face social networks, and several other mediating and moderating variables will also be analyzed.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Smoking
  • Behavioral: smoking cessation aides
    All participants will receive 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start.
  • Behavioral: Twitter
    Twitter quit-smoking group
  • Experimental: Twitter
    Experimental participants are assigned a 20-person twitter quit-smoking group to interact with, are instructed to use Twitter-enabled interactive peer messaging,and are sent daily messages to encourage interaction. The baseline intervention 'smoking cessation aides' is also provided.
    Interventions:
    • Behavioral: smoking cessation aides
    • Behavioral: Twitter
  • Active Comparator: Control
    Control participants are not assigned to a twitter group. The baseline intervention 'smoking cessation aides' is also provided.
    Intervention: Behavioral: smoking cessation aides
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
280
December 2013
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • must have smoked 100 cigarettes during their lifetime
  • must currently smoke 5 or more cigarettes a day
  • must be in the preparation stage of quitting smoking
  • ages 18-59 years
  • English speaking
  • have a mobile phone with an unlimited texting plan and internet access
  • use text messaging at least once a week
  • use Facebook daily
  • have an active email account
  • live in the continental USA

Exclusion Criteria:

  • a medical condition that is contra-indicated for nicotine replacement therapy:
  • pregnant
  • breast feeding
  • a recent heart attack
  • an irregular heartbeat
  • high blood pressure not controlled with medication
  • skin allergies to adhesive tape or serious skin problems
  • taking a prescription medicine for depression or anxiety
  • use drugs or marijuana regularly
  • live in the same household with another participant
Both
18 Years to 59 Years
Yes
Contact: Doug Calder, BA (949) 798-9647 dcalder@uci.edu
Contact: Cornelia Pechmann, PhD 949-824-4058 cpechman@uci.edu
United States
 
NCT01602536
1R34DA030538-01A1
No
Cornelia Pechmann, University of California, Irvine
University of California, Irvine
Not Provided
Principal Investigator: Cornelia Pechmann, PhD University of California, Irvine
University of California, Irvine
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP